Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
| Autor: | Daniela Gebhard, Albert Schömig, Adnan Kastrati, Werner Koch, Dirk Sibbing, N. Von Beckerath, Julia Stegherr, Tibor Schuster, Julinda Mehilli, Siegmund Braun, Tanja Morath |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Ticlopidine CYP2C19 Pharmacology Gastroenterology Cohort Studies Polymorphism (computer science) Internal medicine Genetic variation Genotype medicine Humans Allele Alleles Aged Aspirin Polymorphism Genetic business.industry Genetic Variation Hematology Middle Aged Clopidogrel Cytochrome P-450 CYP2C19 Pharmacogenetics Female Stents Aryl Hydrocarbon Hydroxylases business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Journal of thrombosis and haemostasis : JTH. 8(8) |
| ISSN: | 1538-7836 |
| Popis: | Summary. Background: With the cytochrome P450 CYP2C19*2 (*2) allelic variant resulting in complete loss of enzyme function and the CYP2C19*17 (*17) variant being linked to increased transcriptional activity with extensive metabolism of CYP2C19 substrates, two common variants of the CYP2C19 gene have been explored recently. Currently, the isolated and interactive impacts of both variants on the antiplatelet effects of chronic clopidogrel therapy are unknown. Objectives: The aim of this study was to assess the isolated and interactive impacts of *2 and *17 on clopidogrel responsiveness in patients under clopidogrel maintenance treatment. Methods: Patients (n = 986) eligible for this study were under therapy with coronary stent-related chronic treatment with aspirin and clopidogrel. The ADP-induced platelet aggregation was measured on a Multiplate analyzer (in AU*min), and genotypes were determined with a TaqMan assay. Results: Platelet aggregation values were significantly higher in carriers of at least one *2 allele than in homozygous wild-type allele carriers (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text